^
    1year
    A Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation-Positive Cancers (clinicaltrials.gov)
    P1, N=140, Recruiting, Black Diamond Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D
    |
    BDTX-4933
    1year
    A Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation-Positive Cancers (clinicaltrials.gov)
    P1, N=140, Not yet recruiting, Black Diamond Therapeutics, Inc.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D
    |
    BDTX-4933
    over1year
    Preclinical efficacy of BDTX-4933, a brain penetrant MasterKey inhibitor targeting oncogenic BRAF Class I/II/III mutations (AACR-NCI-EORTC 2022)
    BDTX-4933 achieves on-target inhibition of the RAF-MEK-ERK signaling pathway and anti-tumor activity in multiple preclinical tumor models, including intracranial models. IND-enabling studies for BDTX-4933 are underway.
    Preclinical
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600 • BRAF wild-type
    |
    BDTX-4933